Y-mAbs Therapeutics Inc.

750 Third Avenue, 9th Floor
New York
New York
10017
United States

Tel: 212-847-9841

About Y-mAbs Therapeutics Inc.

YmAbs is a clinical stage biopharmaceutical company focused on developing new cancer treatments through immunotherapies. In addition, YmAbs utilizes its platform technologies to create next-generation humanized, affinity matured bispecific antibodies targeting GD2 and B7-H3. To further improve our bispecific antibodies, we are collaborating with MSK on the development of a novel human protein tag that dimerizes T-cell engaging bispecific antibodies, which enables higher tumor binding and results in a longer serum half-life and a significantly greater T-cell mediated killing of tumor cells. Our treatments could potentially reduce longer-term toxicities associated with current chemotherapeutics and provide the potential for curative therapy even for patients with widespread disease. YmAbs’ goal is to drive multiple product candidates in select solid tumor cancers to FDA licensure. Each candidate has the potential to treat a variety of high-risk cancers.
YEAR FOUNDED:
April 2014
LEADERSHIP:
Founder, President and Head of Business Development and Strategy: Thomas Gad
CEO: Claus Moller
CFO: Bo Kruse
SVP, Head of Technical Operations: Torben Lund-Hansen, PhD
SVP, CMO: Ole Baadsgaard, MD, DMSc
CAREER:
Please click here for YmAbs' job opportunities.

131 articles about Y-mAbs Therapeutics Inc.

Y-mAbs Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares - Nov. 01, 2019

11/1/2019

Y-mAbs Therapeutics, Inc. announced the closing of its public offering of 5,134,750 shares of its common stock, at a public offering price of $28.00 per share, which includes the exercise in full of the underwriters' option to purchase 669,750 additional shares of common stock.
Y-mAbs Announces Proposed Public Offering of Common Stock

10/29/2019

Y-mAbs Therapeutics, Inc. announced the commencement of a registered underwritten public offering of up to $125 million in shares of its common stock.
Y-mAbs Announces Pricing of Public Offering of Common Stock

10/29/2019

The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $125 million.
Y-mAbs Announces Positive Omburtamab Clinical Data

10/28/2019

Y-mAbs Therapeutics, Inc announced a clinical update on omburtamab for the treatment of central nervous system leptomeningeal metastases from neuroblastoma and a number of additional cancer indications.
Y-mAbs Announces Naxitamab Update

10/25/2019

Y-mAbs Therapeutics, Inc. (the Company or Y-mAbs) (Nasdaq: YMAB) today announced that a clinical update on one of the Company’s lead products, naxitamab for the treatment of neuroblastoma and osteosarcoma, was made at the International Society of Pediatric Oncology (SIOP) Annual Congress held in Lyon, France
On the Heels of bluebird bio Collaboration, Gritstone Secures $100 Million in IPO

9/28/2018

Emeryville, Calif.-based Gritstone Oncology hits the ground running today on the Nasdaq Exchange after raising $100 million in an initial public offering.
Updated: Y-mAbs Therapeutics Looks at a $96 Million IPO

9/21/2018

New York-based Y-mAbs Therapeutics will look at securing $96 million through an initial public offering to support development of its antibody-based therapeutic treatments for cancer.
MabVax Therapeutics Grants Exclusive Sublicense to Y-mAbs Therapeutics for Patented Neuroblastoma Vaccine

7/3/2018

MabVax Therapeutics Holdings, Inc. has granted to Y-mAbs Therapeutics, Inc., an exclusive sublicense to a bi-valent ganglioside based vaccine intended to treat neuroblastoma
YmAbs Announces Closing of $30M Extension of Private Equity Placement

11/29/2017

Together, with the $50 million raised in the first closing, the Company has now raised $80 million pursuant to this private placement round.
Genmab Alums' YmAbs Raises $50M

10/24/2017

The cash enables YmAbs to focus on bringing the company's lead compound through the final steps of the regulatory pathway towards approval.
FDA Calls Y-mAbs, Memorial Sloan-Kettering Cancer Center's Pediatric Cancer Drug a Breakthrough

6/8/2017